The FDA has extended Exelixis' NDA review for zanzalintinib in combination with atezolizumab/Tecentriq for metastatic colorectal cancer by three months, moving the action date to March 3, 2027 after updated safety and efficacy data were deemed a major amendment. The development of zanzalintinib as a next-generation cancer therapy continues, with the delay potentially impacting timelines for patients, investors, and partners awaiting a decision.

Health· Sep 11, 2026

Facts from Wikidata (CC0). Image by Exelixis via Wikimedia Commons (Public domain).

Exelixis

American biotechnology company

0members1here now

Ask Genius Site

Site Journal

Feed Discussions About

Sort by

Content type

Latest Exelixis news and discussion

Sort by

Content type

Exelixis· Health · 10 sources · Sep 11, 2026Story

FDA Extends Exelixis Drug Review to March 2027

Health· Sep 11, 2026

Facts from Wikidata (CC0). Image by Exelixis via Wikimedia Commons (Public domain).

Exelixis across IJR

Ask Genius by OpenServe about Exelixis Create in Studio Build a game Watch videos

About Exelixis

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

members

here now

Country: United States
Headquarters: South San Francisco
Inception: 1994
Website: http://www.exelixis.com

Coverage spread L24 / C29 / R47

Everything about Exelixis →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

Exelixis across IJR

Ask Genius by OpenServe about Exelixis Create in Studio Build a game Watch videos